Clinical Scorecard: Systematic Review of [18F]FDG-PET/CT Imaging in Pulmonary Sarcoidosis
At a Glance
Category
Detail
Condition
Pulmonary sarcoidosis, a multisystem inflammatory disease with non-necrotising granulomas primarily affecting lung parenchyma and mediastinal lymph nodes
Key Mechanisms
Inflammatory granuloma formation detected by FDG uptake on PET/CT imaging reflecting active inflammation
Target Population
Patients with suspected or confirmed pulmonary sarcoidosis, including those with variable disease activity and severity
Care Setting
Specialist respiratory and nuclear medicine settings for diagnosis and disease activity assessment
Key Highlights
Pulmonary sarcoidosis diagnosis relies on clinical, radiological, and histological criteria; CT is standard imaging but may be nonspecific
FDG-PET/CT is a sensitive modality detecting inflammatory activity potentially before morphological changes appear on CT
No prior systematic reviews or meta-analyses have comprehensively assessed FDG-PET/CT diagnostic performance and correlation with lung function in pulmonary sarcoidosis
Guideline-Based Recommendations
Diagnosis
Diagnosis requires clinically compatible presentation, radiological evidence, and histological confirmation of non-necrotising granulomas
CT imaging is standard but may require further investigation due to nonspecific findings
FDG-PET/CT can be used to detect active inflammation and support diagnosis, especially in subclinical or ambiguous cases
Management
Treatment decisions guided by disease severity and activity; many cases resolve spontaneously without intervention
FDG-PET/CT may assist in assessing disease activity and guiding treatment response monitoring
Monitoring & Follow-up
Serial FDG-PET/CT scans can be used to monitor metabolic activity and correlate with functional lung parameters such as FVC and DLCO
Functional assessments should be integrated with imaging findings for comprehensive disease monitoring
Risks
Potential for false positives/negatives in FDG-PET/CT necessitates correlation with clinical and histological data
Radiation exposure from PET/CT imaging should be considered in repeated assessments
Patient & Prescribing Data
Patients with histologically or clinically confirmed pulmonary sarcoidosis prior to therapy initiation or under treatment
FDG-PET/CT metabolic activity (SUVmax) correlates with disease severity and may predict treatment response; however, variability exists and further validation is needed
Clinical Best Practices
Use ATS/ERS/WASOG criteria for standardized diagnosis of pulmonary sarcoidosis
Incorporate FDG-PET/CT imaging to detect active inflammation especially when CT findings are inconclusive
Combine imaging results with pulmonary function tests to guide management and monitor treatment efficacy
Apply rigorous quality and bias assessment tools (e.g., QUADAS-2) when interpreting diagnostic studies
Consider multidisciplinary evaluation including pulmonology, radiology, and pathology for optimal patient care
